Nice post. I have been reading some regular chatter about Biogen being a tasty morsel takeover target for the likes of Roche, or Pfizer if Trumps tax plan pushes through. What if any effect would that have on an announcement of a partnership with AVXL. Possibly a delay due to a quiet period? My hope is that CM has not tied up our hands too much with the MTA.